Hollow metal–organic framework-based, stimulator of interferon genes pathway-activating nanovaccines for tumor immunotherapy-Reference-Cited by-同舟云学术

Hollow metal–organic framework-based, stimulator of interferon genes pathway-activating nanovaccines for tumor immunotherapy

Published:2024 Issue:1 Volume:6 Page:72-78
ISSN:2516-0230
Container-title:Nanoscale Advances
language:en
Short-container-title:Nanoscale Adv.

Author:

Zhao Yilei¹,Song Ruinan¹,Zhang Zhen²,Hu Houyang¹,Ning Wenli³,Duan Xiuying¹,Jiao Jianwei⁴,Fu Xiao³,Zhang Guiqiang¹⁵^ORCID

Affiliation:

1. Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China

2. Jinan Vocational College of Nursing, Jinan, Shandong 250102, China

3. School of Stomatology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong 250021, China

4. State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Science, Beijing 100101, China

5. Shandong Hongkui Medical Laboratory Co., Ltd, Jinan 271100, P. R. China

Abstract

Stimulator of interferon genes pathway-activating nanovaccines were constructed by a synergistic approach of etching and surface functionalization, which could trigger a robust immune response to inhibit tumor growth.

Funder

Natural Science Foundation of Shandong Province

Publisher

Royal Society of Chemistry (RSC)

Subject

General Engineering,General Materials Science,General Chemistry,Atomic and Molecular Physics, and Optics,Bioengineering

Link

http://pubs.rsc.org/en/content/articlepdf/2024/NA/D3NA00867C

Reference26 articles.

1. Cancer immunotherapy: moving beyond current vaccines

2. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy

3. Engineered therapeutic nanovaccine against chronic hepatitis B virus infection

4. Towards personalized, tumour-specific, therapeutic vaccines for cancer

5. Strategy and clinical application of up-regulating cross presentation by DCs in anti-tumor therapy